Core Viewpoint - Starcoin Group Limited (formerly known as Innovative Pharmaceutical Biotech Limited) experienced a significant stock price drop, with a decline exceeding 70% following a notification from the Hong Kong Stock Exchange regarding insufficient operational levels and asset value to support continued listing [1][2]. Group 1: Company Announcement and Stock Performance - On November 14, 2025, the company received a letter from the Stock Exchange indicating that it failed to maintain sufficient operational levels and asset value, leading to a decision to suspend trading of its shares on November 26, 2025 [2][3]. - The company had previously announced a failed placement agreement to issue up to 145 million shares at HKD 0.415 per share, as the conditions precedent were not met by September 11, 2025 [1][3]. Group 2: Financial Performance - For the fiscal year ending March 31, 2025, the company reported a revenue of HKD 2.091 million, a year-on-year decrease of 68.28%, and a net loss attributable to shareholders of HKD 346 million, compared to a profit of HKD 103 million in the previous year [5]. - The basic earnings per share for the reporting period were -HKD 0.2001, with net cash flow from operating activities at -HKD 10.555 million, a decrease of HKD 2.276 million year-on-year [5].
闪崩超70%，大利空暴击